10 funding opportunities are listed in this category
2010 Thomas E. Heftler Migraine Research Award
The American Headache Society® (AHS) and the Migraine Research Foundation (MRF) announce the 2010 Thomas E. Heftler Migraine Research Award. The $10,000 award will recognize the most innovative research proposal in migraine by a neurology resident or headache medicine fellow in an accredited U.S. program. Both clinical and basic science proposals will be considered. Reviewers will look for innovation, impact, and importance to the field of migraine research.The Migraine Research Foundation created and funded the award in memory of Mr. Heftler who was a founding member of the Board of Directors of the Migraine Research Foundation until his untimely death in June 2007. The Migraine Research Foundation is the only organization whose sole purpose is to raise funds for innovative scientific research to further the understanding of the causes and mechanisms of migraine, to develop improvements in treatment, and to find the cure.The American Headache Society® is a professional organization comprised of physicians and other health care professionals dedicated to improving the care and lives of headache sufferers.The criteria are: (1) the quality of the research proposal; (2) the potential for the research to contribute to the advancement of the field of headache medicine; and (3) the quality of the research environment. Awardees must submit a progress report after 6 months of work, an abstract to the 2012 AHS Annual Scientific Meeting to be reviewed for presentation, and a manuscript based on this work to the journal Headache. Headache has the first right of refusal for the manuscript.To be considered for this award, the completed application form and all supporting documents must be received by the AHS Executive Offices no later than 5:00pm EST on March 25, 2010. * Proposals due March 25, 2010 * Winner announced April 15, 2010 * Award research to commence July 1, 2010Please contact the American Headache Society® if you have any questions.American Headache Society®19 Mantua Rd.Mount Royal, NJ 08061Phone: 856-423-0043Fax: 856-423-0082ahshq@talley.com
Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease
ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.
As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.
ADDF FUNDING PROGRAMS • ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.
• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.
• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs. RESEARCH FUNDING PRIORITIES • Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies. • Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk. GENERAL SUBMISSION GUIDELINES Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.
APPLICATION PROCEDURE Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.
ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).
If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:Alzheimer’s Drug Discovery Foundation1414 Avenue of the Americas, Suite 1502New York, NY 10019
Request for Applications for Projects With the Potential to Advance Basic Scientific and Translational Brain Aneurysm Research
The Brain Aneurysm Foundation invites applications for basic scientific research directed at early detection, improved treatment modalities, and technological advances that will ultimately improve outcomes for patients with brain aneurysms. Any project with the potential to advance basic scientific and translational brain aneurysm research will be considered. Clinical projects will not be funded. The application due date is April 30, 2010. When doing the budget portion of the application, please budget for the highest possible amount to be awarded, $40,000, even though you may receive a lesser amount. Please contact Christine Buckley at 781 826 5556 or christine@bafound.org with any questions or concerns.
Brain Aneurysm Foundation 269 Hanover Street, Building 3 Hanover, MA 02339 Phone: 781-826-5556 or toll free 888-272-4602 Email: office@bafound.org
American Foundation for Suicide Prevention Grants Program
APPLICATIONS MAY NOT BE SUBMITTED SOLELY IN PAPER FORM. AN ELECTRONIC COPY MUST BE INCLUDED.
Cycle 1 Due date: June 1, 2010Email: grants@afsp.org for all grant submissions and questions related to grant submissions.
EligibilityAFSP research grants support studies that aim to increase understanding of the causes of suicide and factors related to suicide risk, or to test treatments and other interventions designed to prevent suicide. Investigators from all academic disciplines are eligible to apply, and both basic science and applied research projects will be considered, providing the study has an essential focus on suicide or suicide prevention. AFSP grants are awarded for one or two-year periods. Grant applications are not accepted from for-profit organizations, or from federal or state government agencies.An individual can hold only one AFSP grant at a time. As a general policy, an individual can hold only one AFSP grant at a time. During the second year of funding (of the first year in the case of one-year grant) a current grant holder may apply for another AFSP grant which if approved, would start after the first grant period has ended and the final progress report and financial statement has been submitted. In reviewing the new application, consideration will be given to the applicant's progress on the current application. Applicants should carefully review the grant policy statement for additional guidelines and restrictions. Grant applications that do not conform to the stated policies will not be reviewed. A grant application submitted by an applicant who has previously held an AFSP grant and has not submitted a Final Report within the prescribed period (i.e., 60 days following grant completion or termination) will not be reviewed.New grantees must begin their studies within six months of the approved start date. Failure to begin the study within this time frame may result in withdrawal of the grant award.A grant may only be resubmitted twice.
Grant CategoriesAFSP offers six types of research grants: * Distinguished Investigator Grants for up to $100,000 over two years are awarded to investigators at the level of associate professor or higher with an established record of research and publication on suicide. * Standard Research Grants for up to $75,000 over two years are awarded to individual investigators at any level. * Linked Standard Research Grants for three or more sites of up to $225,000 over two years are awarded to investigators at any level. * Young Investigator Grants for up to $85,000 over two years are awarded to investigators at the level of assistant professor or lower. In addition to a maximum of $75,000 for the investigator’s research, these grants provide an additional $10,000 ($5,000 per year) for an established suicide researcher who will mentor the Young Investigator. * Postdoctoral Research Fellowships for up to $100,000 over two years are awarded to investigators who have received a Ph.D., M.D., or other doctoral degree within the preceding six years and have not had more than three years of fellowship support. Fellows receive a progressive stipend of $42,000 in the first year and $46,000 in the second, with an institutional allowance of $6,000 per year. * Pilot Grants for up to $30,000 over one or two years are awarded to investigators at any level. These grants provide seed money for new projects that have the potential to lead to subsequent larger investigations.
American Foundation for Suicide Prevention120 Wall Street, 22nd FloorNew York, NY 10005Toll-free: 1-888-333-AFSP (2377)Phone: (212) 363-3500Fax: (212) 363-6237Website: www.afsp.orgEmail: inquiry@afsp.org
National Niemann-Pick Disease Foundation Peter G. Pentchev Research Fellowship
The National Niemann-Pick Disease Foundation (NNPDF) invites applications for post-doctoral research fellowships examining the biology of Niemann-Pick Type C (NPC) disease, a lethal neurodegenerative disease for which there are no effective therapies. M.D., Ph.D. and D.V.M. postdoctoral researchers are eligible to apply for funding to improve our understanding of the biology and pathogenesis of NPC disease. Preference will be given to research projects developing new therapies for NPC, and identifying biomarkers of disease activity for diagnosis and clinical trials. The fellowships provide support of $50,000 per annum for two years and may be renewable based on performance. Applicants must be currently associated with a recognized laboratory. Applications are due May 1, 2010, and should be submitted by email to the Research Committee Chair. Applicants will be informed of the funding decision by August 15, 2010, via email. Fellowships will be awarded to begin September 1, 2010. For further information please contact Janet Ward Pease, Research Committee Chair, National Niemann-Pick Disease Foundation.
National Niemann-Pick Disease Foundation (NNPDF) P.O. Box 49 401 Madison Avenue, Suite B Fort Atkinson, WI 53538 Phone/Email Toll Free: 1-877-287-3672 Office: 1-920-563-0930 Fax : 1-920-563-0931 Email: nnpdf@nnpdf.org
1
